sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.

Timeline

Start

2019-09-20

Primary completion

2021-02-05

Completion

2022-06-30

Publications

• VanderWeele DJ, Kocherginsky M, Munir S, Martone B, Sagar V, Morgans A, Stadler WM, Abdulkadir S, Hussain M. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec;20(6):575-580. doi: 10.1016/j.clgc.2022.08.012. Epub 2022 Sep 7.

Drugs

Indications